Fulgent Genetics (FLGT) EBT (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of EBT data on file, last reported at -$26.0 million in Q1 2026.

• Quarterly EBT fell 121.6% year-over-year to -$26.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.5 million (up 49.24% YoY) and the FY2025 annual result came in at -$8.3 million, up 82.34% from the prior year.
• EBT declined to -$26.0 million in Q1 2026 per FLGT's latest filing, from $32.5 million in the prior quarter.
• The five-year high for EBT was $202.0 million in Q1 2022, with the low at -$33.5 million in Q4 2022.
• Average EBT over 5 years is $4.5 million, with a median of -$11.2 million recorded in 2024.
• Year-over-year, EBT sank 370.15% in 2024 and jumped 1219.4% in 2025.
• Fulgent Genetics' EBT stood at -$33.5 million in 2022, then soared by 106.78% to $2.3 million in 2023, then tumbled by 227.95% to -$2.9 million in 2024, then jumped by 1219.4% to $32.5 million in 2025, then plunged by 179.97% to -$26.0 million in 2026.
• Business Quant data shows FLGT's EBT at -$26.0 million in Q1 2026, $32.5 million in Q4 2025, and -$7.5 million in Q3 2025.